VIII. Medications and Medical Interventions

VIII. 13 Statins (HMG-CoA Reductase Inhibitors)

Statins are among the rare drugs that may actually benefit the gut flora – linked to a richer, more balanced microbiota that partly offsets obesity-related dysbiosis.

Statins – A Fungal Discovery That Changed Cardiovascular Medicine

Statins are among the most prescribed drugs in the world – and one of the few medication classes where population-level data suggest a net neutral-to-positive effect on gut microbial diversity. [634]

Anecdote

In 1971, a Japanese biochemist named Akira Endo was working at the Sankyo pharmaceutical company in Tokyo with a specific and counterintuitive hypothesis: if bacteria depend on isoprenoid pathways for cell membrane integrity, some fungi may have evolved inhibitors of these pathways as competitive weapons against bacterial rivals. Endo and his team screened over 6,000 fungal strains over three years. In 1973, they isolated mevastatin – later called compactin – from a blue-green mould contaminating a grain sample from Kyoto: Penicillium citrinum. The compound turned out to inhibit not bacterial membrane synthesis but the human enzyme HMG-CoA reductase, the rate-limiting step in hepatic cholesterol biosynthesis. Mevastatin was shelved following early animal toxicity concerns, but the chemical class was real. By 1987, Merck launched lovastatin, the first commercially available statin. Today, an estimated 200 million people take a statin daily. What their prescribers and patients rarely discuss is that the organisms Endo originally had in mind – bacteria – are precisely the community most shaped by decades of chronic statin exposure in the gut.

Statins lower LDL cholesterol by competitively inhibiting hepatic HMG-CoA reductase. The gut lumen receives significant drug exposure before hepatic first-pass extraction. At luminal concentrations that may substantially exceed plasma levels, statins interact with gut microbiota through at least three distinct mechanisms: direct antimicrobial activity, indirect modulation of the bile acid pool, and suppression of intestinal inflammatory tone.

Statins possess intrinsic antimicrobial properties, particularly against gram-positive bacteria. Simvastatin, atorvastatin, and lovastatin inhibit the growth of Staphylococcus aureus, Enterococcus faecalis, and selected Streptococcus species by disrupting isoprenoid synthesis pathways required for bacterial cell membrane integrity. At luminal concentrations – where statin exposure is prolonged by enterohepatic recirculation – the selective pressure on gram-positive commensal communities may be clinically relevant.

The bile acid pathway is a second, indirect mechanism. Statins reduce hepatic cholesterol availability, altering the composition and volume of primary bile acids entering the gut. Primary bile acids are the exclusive substrate for microbial conversion to secondary bile acids (deoxycholic acid, lithocholic acid) – a process carried out by Clostridiales and Lachnospiraceae. Secondary bile acids regulate gut ecosystem composition as both antimicrobial agents and signalling molecules for nuclear receptors FXR^[G] and TGR5^[G]. Statin-induced changes in the primary bile acid pool propagate downstream as changes in microbial community ecology.

A landmark study by Vieira-Silva et al. published in Nature in 2020 analysed quantitative faecal metagenomes from the MetaCardis BMI-spectrum cohort (n=888). The central finding was not the enrichment of any favourable genus but the reduced prevalence of a dysbiotic configuration: the inflammation-associated Bact2 enterotype – characterised by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell density – was present in 6% of obese statin users versus 19% of obese non-users, essentially matching the 4% observed in non-obese participants. The association was validated in the MetaCardis cardiovascular disease subset (n=282) and in the independent Flemish Gut Flora Project cohort (n=2,345). The authors proposed that the effect may operate partly through modulation of bile acid metabolism and the anti-inflammatory properties of statins. The data are observational and cross-sectional, so they do not establish the direction of causality. [634]

In the context of FMT treatment, statin use is not a contraindication. The available evidence suggests a net neutral-to-beneficial effect on gut ecology in most patients. However, statins create a pre-existing microbiota signature – mild enrichment of Bacteroidetes and modest reduction in some gram-positive butyrate producers – that may modulate engraftment dynamics. Patients on long-term statin therapy should be identified in the pre-FMT medication review; dose continuity is maintained throughout all treatment phases.

Managing Gut Health During Statin Therapy

In clinical microbiota care, statin use is classified as potentially modifying rather than actively harmful. The primary tasks are documentation of the statin type, dose, and duration, and monitoring for symptoms that may reflect statin–microbiota interactions.

Patients on statins who experience persistent gastrointestinal symptoms – particularly altered bowel frequency, bloating, or cramping – should have microbiota context evaluated. These symptoms are often attributed to direct statin toxicity but may also reflect disruption of gram-positive commensal communities in individuals with pre-existing dysbiosis.

Co-prescription of statins with antibiotics or proton pump inhibitors should be flagged in the pre-FMT medication review. The combined microbiota impact may exceed the sum of individual effects, particularly when statin-induced bile acid shifts are compounded by acid suppression or direct antimicrobial disruption.

Dietary fibre intake ≥25g/day and regular fermented food consumption support the SCFA-producing communities that statins modestly reduce and maximise the observed cardiometabolic benefits of the statin–microbiota interaction.

Microbiota Effects

Statin use is associated with a lower prevalence of the inflammation-associated Bact2 dysbiotic enterotype in the multi-country European MetaCardis cohort (n=888): Bact2 prevalence was 6% among obese statin users and 19% among obese non-users. The association is observational and cross-sectional. [634]
Statins exert intrinsic antimicrobial activity against gram-positive bacteria through inhibition of isoprenoid membrane synthesis, modestly reducing some Firmicutes-associated butyrate producers at luminal concentrations. [635]
Statin use can be accompanied by shifts in gut microbiota composition and bile acid metabolism; the observed microbiota changes may act in part through bile acid signaling (FXR and TGR5 receptors), although the precise causal chain in humans remains unclear.
Atorvastatin and simvastatin are associated with enrichment of Lactobacillaceae and reduction of Enterobacteriaceae in hypercholesterolaemic patients, consistent with reduced intestinal inflammatory tone. [635]
The net gut microbiota effect of statins appears modestly favourable in cardiometabolic patients – a rare distinction among commonly prescribed medication classes. [634]
There is no evidence that statin therapy should be suspended before or after FMT; the baseline gut microbiota of statin users is, however, documented to differ from that of non-users – at population level, statin therapy is associated with a lower prevalence of the dysbiotic (Bacteroides 2) enterotype [634]. The clinical question is therefore not discontinuation but how this modified baseline community interacts with donor engraftment; no study has yet addressed this.
Statins are documented to alter gut microbiota composition and the bile-acid pool in animal models (PXR-dependent dysbiosis), and secondary bile acids may influence skeletal-muscle metabolism via the microbiota-gut-muscle axis; however, a causal role of this mechanism in statin-associated myopathy remains hypothetical and is not yet supported by direct human evidence. [637]

Patient Guidance

Continue statins as prescribed throughout FMT treatment – do not modify statin doses based on gut symptom concerns without explicit physician guidance.
Maintain dietary fibre intake of ≥25g/day to support SCFA-producing communities that statins modestly reduce.
Include fermented foods (yogurt, kefir, fermented vegetables) regularly to sustain community balance alongside statin therapy.
Report persistent gastrointestinal symptoms during statin use to your clinical team – some statin GI effects reflect microbiota dynamics rather than direct drug toxicity.
Avoid combining statin therapy with unnecessary antibiotic courses – the combined disruption of bile acid ecology and antimicrobial pressure exceeds that of either agent alone.
If your statin type or dose changes during FMT consolidation, notify the clinical team – altered bile acid dynamics may affect engraftment trajectory.

🦪

Clinical Pearl Statins are among the few prescription medications with population-level microbiota data: in the 888-participant MetaCardis cohort (Vieira-Silva et al., 2020, Nature), the inflammation-associated Bact2 dysbiotic enterotype was present in 6% of obese statin users versus 19% of obese non-users. Statin use therefore tracked with a lower prevalence of the dysbiotic configuration rather than with enrichment of any "good" genus. The data are observational and do not support a causal claim; a microbiota-mediated component of the anti-inflammatory action of statins, via bile acid pool modulation, remains hypothetical.

References

[634] Vieira-Silva S, Falony G, Belda E et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020. Link

This study used quantitative faecal metagenomes from the MetaCardis Body Mass Index Spectrum cohort (n=888) to examine the obesity-associated Bacteroides2 (Bact2) enterotype, characterized by high Bacteroides, low Faecalibacterium and low microbial cell density. Statin therapy emerged as a key covariate of microbiome diversification. In the non-statin subcohort, Bact2 prevalence rose from 3.90% in lean/overweight to 17.73% in obese individuals. Bact2 carriers had higher systemic inflammation than predicted by obesity alone, marking Bact2 as a dysbiotic constellation linked to obesity and inflammation, with statins potentially modulating this association.

[635] Dias AM, Cordeiro G, Estevinho MM, et al. Gut bacterial microbiome composition and statin intake—A systematic review. . 2020. Link

A systematic review of statin–gut microbiome interactions pooling animal and human studies. Statins exert direct antimicrobial activity (chiefly against Gram-positive bacteria, via disruption of bacterial cell-surface structures), and statin use is associated with shifts in gut microbiome composition; several studies report enrichment of commensal taxa (e.g. Lactobacillaceae) and reduction of pro-inflammatory Enterobacteriaceae in hypercholesterolaemic patients. The review contextualises the pleiotropic, microbiota-modulating effects of statins.

[637] Mancin L, Wu GD, Paoli A. Gut microbiota-bile acid-skeletal muscle axis. . 2023. Link

The Trends in Microbiology review by Mancin, Wu and Paoli (online 2022, print 2023) systematizes the gut microbiota-bile acid-skeletal muscle axis. The gut microbiota converts primary bile acids into metabolically active secondary bile acids that, as ligands of the farnesoid X receptor (FXR) and TGR5, influence skeletal-muscle metabolism, mass and function. Dysbiosis (low diversity, unstable composition) impairs muscle homeostasis via an altered bile-acid pool. The framework provides the conceptual basis for the hypothesis that statin-induced bile-acid and microbiota changes could affect muscle — while direct human causal evidence for statin-associated myopathy remains lacking.